Tag: evidence

Adverse events were generally low-grade, transient, and readily manageable

New York City, NY, July 03, 2025 (GLOBE NEWSWIRE) -- In 2025, Nixol, a plant-based dietary supplement, made its debut in the United Kingdom and Ireland, marking a significant entry into the wellness supplement market. Designed to support healthy weight management, boost metabolism, and curb cravings, Nixol has positioned itself as a natural, vegan-friendly alternative to traditional weight loss solutions. Unlike products that rely on synthetic stimulants or restrictive diets, Nixol leverages a blend of carefully selected, science-backed ingredients to promote sustainable fat reduction and overall well-being. This article provides an in-depth exploration of Nixol’s launch, its formulation, claims, scientific backing, customer feedback, and the broader context of its market entry, while critically examining its potential effectiveness and limitations. Visit Official Website 

In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.

ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- The Dr. Michael Lebow Scholarship for Future Doctors is now officially open for applications, inviting undergraduate students across the United States to compete for a one-time academic award designed to support and encourage future leaders in the healthcare field. This prestigious scholarship, created by esteemed vascular surgeon Dr. Michael Lebow, is committed to recognizing students who have demonstrated academic excellence, a passion for medicine, and a clear vision for positively impacting the healthcare industry.

EINDHOVEN, the Netherlands, July 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announced the submission of two major regulatory applications for its ARC-EX System. The Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) seeking clearance to expand its indication for home use. In parallel, ONWARD has filed an application with the notified body for CE Mark certification in accordance with the European Union Medical Device Regulation (MDR) to enable commercialization of the ARC-EX System in the EU. Completed in June, these submissions represent significant milestones as the Company advances its mission to bring breakthrough therapies to people with SCI around the world.

MCLEAN, Va., June 30, 2025 (GLOBE NEWSWIRE) -- The Thought Leadership & Innovation Foundation (TLI), a nonprofit at the forefront of health innovation, today announced the release of a groundbreaking white paper, A Model for Non-Profit Cooperation to Benefit Chronic Disease Communities. This report outlines TLI’s dynamic, multi-sectoral approach to supporting underserved patient populations through collaboration, data innovation, and stakeholder engagement.